Common Cancer-associated Antigens (CAAs) Vaccine Market, Global Outlook and Forecast 2023-2028

Report ID: 1212946 | Published Date: Jan 2025 | No. of Page: 62 | Base Year: 2024 | Rating: 5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Introduction to Research & Analysis Reports
    1.1 Common Cancer-associated Antigens (CAAs) Vaccine Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Common Cancer-associated Antigens (CAAs) Vaccine Overall Market Size
    2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size: 2021 VS 2028
    2.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size, Prospects & Forecasts: 2017-2028
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Common Cancer-associated Antigens (CAAs) Vaccine Players in Global Market
    3.2 Top Global Common Cancer-associated Antigens (CAAs) Vaccine Companies Ranked by Revenue
    3.3 Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue by Companies
    3.4 Top 3 and Top 5 Common Cancer-associated Antigens (CAAs) Vaccine Companies in Global Market, by Revenue in 2021
    3.5 Global Companies Common Cancer-associated Antigens (CAAs) Vaccine Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Common Cancer-associated Antigens (CAAs) Vaccine Players in Global Market
        3.6.1 List of Global Tier 1 Common Cancer-associated Antigens (CAAs) Vaccine Companies
        3.6.2 List of Global Tier 2 and Tier 3 Common Cancer-associated Antigens (CAAs) Vaccine Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 by Type - Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Markets, 2021 & 2028
        4.1.2 Tecemotide
        4.1.3 Astuprotimut-R
        4.1.4 Tertomotide
        4.1.5 Nelipepimut-S
        4.1.6 Others
    4.2 By Type - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue & Forecasts
        4.2.1 By Type - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2017-2022
        4.2.2 By Type - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2023-2028
        4.2.3 By Type - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2017-2028
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2021 & 2028
        5.1.2 Pediatrics
        5.1.3 Adults
    5.2 By Application - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue & Forecasts
        5.2.1 By Application - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2017-2022
        5.2.2 By Application - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2023-2028
        5.2.3 By Application - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2017-2028
6 Sights by Region
    6.1 By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2021 & 2028
    6.2 By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue & Forecasts
        6.2.1 By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2017-2022
        6.2.2 By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2023-2028
        6.2.3 By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2017-2028
    6.3 North America
        6.3.1 By Country - North America Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2017-2028
        6.3.2 US Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.3.3 Canada Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.3.4 Mexico Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
    6.4 Europe
        6.4.1 By Country - Europe Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2017-2028
        6.4.2 Germany Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.4.3 France Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.4.4 U.K. Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.4.5 Italy Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.4.6 Russia Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.4.7 Nordic Countries Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.4.8 Benelux Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
    6.5 Asia
        6.5.1 By Region - Asia Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2017-2028
        6.5.2 China Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.5.3 Japan Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.5.4 South Korea Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.5.5 Southeast Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.5.6 India Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
    6.6 South America
        6.6.1 By Country - South America Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2017-2028
        6.6.2 Brazil Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.6.3 Argentina Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2017-2028
        6.7.2 Turkey Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.7.3 Israel Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.7.4 Saudi Arabia Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
        6.7.5 UAE Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2017-2028
7 Players Profiles
    7.1 Seattle Genetics
        7.1.1 Seattle Genetics Corporate Summary
        7.1.2 Seattle Genetics Business Overview
        7.1.3 Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
        7.1.4 Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2017-2022)
        7.1.5 Seattle Genetics Key News
    7.2 Merck Serono
        7.2.1 Merck Serono Corporate Summary
        7.2.2 Merck Serono Business Overview
        7.2.3 Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
        7.2.4 Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2017-2022)
        7.2.5 Merck Serono Key News
    7.3 Merck KGaA
        7.3.1 Merck KGaA Corporate Summary
        7.3.2 Merck KGaA Business Overview
        7.3.3 Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
        7.3.4 Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2017-2022)
        7.3.5 Merck KGaA Key News
    7.4 GlaxoSmithKline
        7.4.1 GlaxoSmithKline Corporate Summary
        7.4.2 GlaxoSmithKline Business Overview
        7.4.3 GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
        7.4.4 GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2017-2022)
        7.4.5 GlaxoSmithKline Key News
    7.5 KAEL-GemVax
        7.5.1 KAEL-GemVax Corporate Summary
        7.5.2 KAEL-GemVax Business Overview
        7.5.3 KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
        7.5.4 KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2017-2022)
        7.5.5 KAEL-GemVax Key News
    7.6 SELLAS Life Sciences
        7.6.1 SELLAS Life Sciences Corporate Summary
        7.6.2 SELLAS Life Sciences Business Overview
        7.6.3 SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
        7.6.4 SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2017-2022)
        7.6.5 SELLAS Life Sciences Key News
    7.7 Celldex
        7.7.1 Celldex Corporate Summary
        7.7.2 Celldex Business Overview
        7.7.3 Celldex Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
        7.7.4 Celldex Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2017-2022)
        7.7.5 Celldex Key News
    7.8 Immatics Biotechnologies
        7.8.1 Immatics Biotechnologies Corporate Summary
        7.8.2 Immatics Biotechnologies Business Overview
        7.8.3 Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
        7.8.4 Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2017-2022)
        7.8.5 Immatics Biotechnologies Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

List of Tables
    Table 1. Common Cancer-associated Antigens (CAAs) Vaccine Market Opportunities & Trends in Global Market
    Table 2. Common Cancer-associated Antigens (CAAs) Vaccine Market Drivers in Global Market
    Table 3. Common Cancer-associated Antigens (CAAs) Vaccine Market Restraints in Global Market
    Table 4. Key Players of Common Cancer-associated Antigens (CAAs) Vaccine in Global Market
    Table 5. Top Common Cancer-associated Antigens (CAAs) Vaccine Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Common Cancer-associated Antigens (CAAs) Vaccine Product Type
    Table 9. List of Global Tier 1 Common Cancer-associated Antigens (CAAs) Vaccine Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Common Cancer-associated Antigens (CAAs) Vaccine Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2023-2028
    Table 30. Seattle Genetics Corporate Summary
    Table 31. Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
    Table 32. Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn), (2017-2022)
    Table 33. Merck Serono Corporate Summary
    Table 34. Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
    Table 35. Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn), (2017-2022)
    Table 36. Merck KGaA Corporate Summary
    Table 37. Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
    Table 38. Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn), (2017-2022)
    Table 39. GlaxoSmithKline Corporate Summary
    Table 40. GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
    Table 41. GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn), (2017-2022)
    Table 42. KAEL-GemVax Corporate Summary
    Table 43. KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
    Table 44. KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn), (2017-2022)
    Table 45. SELLAS Life Sciences Corporate Summary
    Table 46. SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
    Table 47. SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn), (2017-2022)
    Table 48. Celldex Corporate Summary
    Table 49. Celldex Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
    Table 50. Celldex Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn), (2017-2022)
    Table 51. Immatics Biotechnologies Corporate Summary
    Table 52. Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
    Table 53. Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Common Cancer-associated Antigens (CAAs) Vaccine Segment by Type in 2021
    Figure 2. Common Cancer-associated Antigens (CAAs) Vaccine Segment by Application in 2021
    Figure 3. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Common Cancer-associated Antigens (CAAs) Vaccine Revenue in 2021
    Figure 8. By Type - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2017-2028
    Figure 12. US Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2017-2028
    Figure 16. Germany Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 17. France Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2017-2028
    Figure 24. China Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 28. India Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2017-2028
    Figure 30. Brazil Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2017-2028
    Figure 33. Turkey Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2017-2028
    Figure 37. Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. Celldex Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 44. Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
62
Frequently Asked Questions
Common Cancer-associated Antigens Vaccine Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Common Cancer-associated Antigens Vaccine Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Common Cancer-associated Antigens Vaccine Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports